Stock Screener App

무료 -

설치하다

0.811

4.40% -0.0373

Biofrontera Inc (BFRI)

개요 뉴스 가격 이력 Financials 토론 예측 주식 분할

Biofrontera Inc 주식(BFRI)의 최신 뉴스

Biofrontera reports rise in Q4 revenue, turns profitable - MSN

If You Invested $1,000 in Biofrontera Inc (BFRI) - Stock Titan

Layoff Watch: Is Biofrontera Inc forming a breakout pattern2026 PostEarnings & High Conviction Buy Zone Alerts - baoquankhu1.vn

Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada

BFRI PE Ratio & Valuation, Is BFRI Overvalued - Intellectia AI

Biofrontera’s New Royalty Agreement Drives Gross Margins Above 82%, Opening Up New Profit Opportunities - Bitget

Biofrontera Inc. (NASDAQ:BFRI) Q4 2025 Earnings Call Transcript - Insider Monkey

Biofrontera Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Biofrontera 2025 Company Overview: Ameluz Photodynamic Therapy, Product Pipeline, and U.S. Market Strategy - Minichart

Biofrontera Earnings Call: Profits Rise, Risks Remain - TipRanks

BFRIW SEC FilingsBiofrontera 10-K, 10-Q, 8-K Forms - Stock Titan

BIOFRONTERA ($BFRI) Releases Q4 2025 Earnings - Quiver Quantitative

[10-K] Biofrontera Inc. Files Annual Report | BFRI SEC FilingForm 10-K - Stock Titan

Biofrontera outlines 80%-85% gross margin target for 2026 following strategic asset acquisition - MSN

Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com

Earnings call transcript: Biofrontera Inc. Q4 2025 sees record revenue growth - Investing.com Australia

Biofrontera 2025 Financial Results: Record Annual & Quarterly RevenueNews and Statistics - IndexBox

Biofrontera Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Biofrontera (BFRI) Q4 2025 Financial Results Transcript - Bitget

Biofrontera (BFRI) Q4 2025 Earnings Transcript - The Globe and Mail

BFRI: Record revenue, improved margins, and clinical progress set up strong 2026 growth - TradingView

Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year - TipRanks

Biofrontera reports record Q4 revenue $17.1M, Q4 gross margin 82.4% and Q4 net income $5.6M - TradingView

Record Q4 for Biofrontera (NASDAQ: BFRI) with 36% revenue growth - Stock Titan

Biofrontera turns Q4 profitable after cutting Ameluz earnout payments - Stock Titan

Price Action: Does Biofrontera Inc have a sustainable dividend2026 Pullbacks & Fast Gain Swing Trade Alerts - baoquankhu1.vn

Nasdaq Moves: Does Biofrontera Inc Equity Warrant have pricing power2026 Snapshot & Real-Time Chart Breakout Alerts - baoquankhu1.vn

Biofrontera Inc expected to post earnings of 20 cents a shareEarnings Preview - TradingView

BFRIWBiofrontera Latest Stock News & Market Updates - Stock Titan

Analysts Offer Insights on Healthcare Companies: OS Therapies Incorporated (OSTX), Legend Biotech (LEGN) and Biofrontera (BFRI) - The Globe and Mail

Biofrontera (BFRI) to Release Earnings on Thursday - Defense World

Are healthcare shares trailing behind Align Technology (ALGN) in performance this year? - Bitget

PTA-Adhoc: Biofrontera AG: Financial Guidance for FY 2026 - TradingView

Market Rankings: Is Biofrontera Inc backed by strong institutional buying2026 Opening Moves & Verified Swing Trading Watchlists - baoquankhu1.vn

Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Bitget

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 - The Manila Times

Biofrontera Inc. to Report Fourth Quarter and Full Year - GlobeNewswire

Biofrontera Inc. (BFRI) upgraded to buy: Here's why - MSN

Biofrontera reports Phase 2b acne trial results for Ameluz PDT - Investing.com India

Biofrontera Reports Positive Phase 2b Acne Trial Results - TipRanks

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - The Manila Times

Biofrontera reports positive Phase 2b Ameluz PDT results for moderate to severe acne - TradingView

Biofrontera Inc. Reports Positive Phase 2b Results - GlobeNewswire

Is Biofrontera Inc. backed by strong institutional buyingQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn

Loss Report: Does Biofrontera Inc have a sustainable dividendDollar Strength & Step-by-Step Trade Execution Guides - baoquankhu1.vn

Biofrontera (BFRI) director awarded 20,000-share employee stock option grant - Stock Titan

Biofrontera grants RSUs and options to... | BFRI Insider Trading - Stock Titan

BFRIW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Will Biofrontera Inc. stock go up in YEAR2025 Top Gainers & Risk Controlled Stock Alerts - mfd.ru

Biofrontera wins patent ruling against Sun Pharma in dispute By Investing.com - Investing.com Australia

Bank Watch: Is Biofrontera Inc a play on infrastructure spendingJuly 2025 Final Week & AI Enhanced Execution Alerts - baoquankhu1.vn

Biofrontera wins patent ruling against Sun Pharma in dispute - Investing.com

Biofrontera reports USPTO decision on Sun Pharma’s challenged claims - TipRanks

Biofrontera Wins Key PTAB Ruling in Sun Patent Dispute - TipRanks

Biofrontera (NASDAQ: BFRI) wins PTAB decision on Sun Pharma patent claims - Stock Titan

U.S. Patent Office Issues Final Written Decision Finding - GlobeNewswire

Gains Recap: Will Biofrontera Inc stock go up in YEAR2025 Trading Recap & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn

Is Biofrontera Inc. stock technically oversoldWeekly Stock Analysis & Community Consensus Trade Signals - mfd.ru

Growth Value: Can Biofrontera Inc Equity Warrant sustain its profitabilityLong Setup & Weekly Breakout Watchlists - baoquankhu1.vn

RDY

$13.45

1.75%

RGC

$24.43

3.13%

ELAN

$24.90

1.88%

NBIX

$127.86

0.64%

VTRS

$13.36

0.53%

UTHR

$531.82

2.03%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개